Search Results

BACK FACT-Cog Languages Arabic Chinese - Simplified Chinese - Traditional Czech Danish Dutch English Estonian French German Greek Hebrew Hungarian Italian Japanese Kannada Korean Latvian Malay Norwegian Polish Portuguese Romanian Russian Slovak Slovene Spanish Swedish Turkish Ukrainian

BACK NFHSI-18 Scoring Downloads Download DOC

FACITtrans Publications OUR PASSION FOR LINGUISTICS IS WHAT DRIVES US Below are selected publications and presentations by our staff, detailing the various approaches and challenges to attaining cross-cultural measurement equivalence. PublicationsTop Your search returned 0 results Translation and linguistic validation of 24 PROMIS item banks into French Ahmed S, Parks-Vernizzi E, Perez B, Arnold B, Boucher A, Hossenbaccus M, Correia H, Bartlett SJ. Qual Life Res. 2024 Aug;33(8):2119-2127 . doi: 10.1007/s11136-024-03690-4. Epub 2024 Jun 12. PMID: 38865068; PMCID: PMC11286690. Translation and Linguistic Validation of the EXACT for Use with COPD Patients in African Countries Savic L., Arnold B., Baily A., Mackey DJ., Olaiya P. Presented at ISOQOL Calgary, October 2023. Winner of the 2023 Outstanding Poster Award Psychometric properties of the Polish version of the FACIT-Sp-12: Assessing spiritual well-being among patients with chronic diseases Machul M., Bredle J., Jurek K., Dobrowolska B. Med Sci Monit. 2023 Nov 16;29:e941769 Achieving Conceptual and Cultural Equivalence in Universal Arabic PROMIS Item Banks Parks-Vernizzi E., Nagy E., Guillen R., Boucher A., Arnold B., Maksud E., Correia H., Bakhsh HR, Bin Sheeha BH, Al-Dhahi M., Al-Hasani R. Presented at ISOQOL Calgary, October 2023. Translation & Linguistic Validation of the FACIT-COST Measuring Financial Toxicity in Cancer Patients Worldwide Savic L., Parks-Vernizzi E., Arnold B., Bredle JM Presented at ISOQOL Calgary, October 2023. Translation & Linguistic Validation of PROMIS SF v2.0 -Physical Function -MS 15a & PROMIS SF v1.0 -Fatigue -MS 8a for use in India & Malaysia Parks-Vernizzi E., Pérez B., Maksud E., Son J., Arnold B., Correia C. Presented at PHO Prague, October 2022. Pediatric and parent proxy Peds-FACT-Br translations and cross-cultural validation: challenges and resolutions Arnold B., Bredle J., Parks-Vernizzi E., Savic L. Presented at ISOQOL Prague, October 2022. Targeting Conceptual Equivalence in the Norwegian Linguistic Validation of Pediatric and Parent Proxy PROMIS Items Parks-Vernizzi E., Boucher A., Arnold B., Correia H., Sletten IN, Garratt A. Presented at PHO Banff, October 2021. Translation and Linguistic Validation of Dutch-Flemish PROMIS Item Banks: Cognitive Function, Itch -Interference, and Self-Efficacy Parks-Vernizzi E., Boucher A., Arnold B., Zonjee V., Correia H., Kuijlaars I., Fischer K., Haverman L., Terwee C. Presented at PHO Banff, October 2021. Psychometric properties of the FACT-G quality of life scale for family caregivers of cancer patients Song L., Tan X., Bredle J., Bennett A.V., Northouse L. Qual Life Res 2020 Aug; 29(8): 2241-2252 Prev 1 2 3 ... 11 1 ... 1 2 3 4 5 6 7 8 9 10 11 ... 11 Next We look forward to serving your study needs. Contact us to get started! ​ FACITtrans is ISO 9001:2015 and ISO 17100:2015 certified.

BACK NFKSI-19 Scoring Downloads Download DOC

BACK FHNSI Languages Afrikaans Arabic Chinese - Simplified Chinese - Traditional Czech Danish Dutch English Estonian Farsi French German Greek Gujarati Hebrew Hindi Italian Japanese Kannada Korean Latvian Lithuanian Malay Malayalam Marathi Norwegian Polish Portuguese Romanian Russian Slovak Spanish Swedish Tagalog Tamil Telugu Thai Turkish Urdu Zulu

BACK FACT-GOG-NTX Languages Afrikaans Arabic Bengali Bosnian Bulgarian Cebuano Chinese - Simplified Chinese - Traditional Croatian Czech Danish Dutch English Finnish French German Greek Gujarati Hebrew Hindi Hungarian Italian Japanese Kannada Korean Latvian Lithuanian Malay Malayalam Marathi Norwegian Polish Portuguese Punjabi Romanian Russian Serbian Sesotho Setswana Slovak Spanish Swedish Tagalog Tamil Telugu Thai Turkish Ukrainian Urdu Vietnamese Xhosa Zulu

Label Claims LABEL CLAIMS INFORMATION RELEVANT TO BOTH FACIT MEASURES AND FACITtrans’ TRANSLATIONS What is a label claim? In the US, the Food and Drug Administration (FDA) is responsible for oversight of medicinal products; the concurrent European Union (EU) organization is called the European Medicines Agency (EMA or EMEA). The package inserts accompanying a drug list all of the medicine’s risks and benefits so that patients and their caregivers are informed of them. In the US these inserts are called “labels”; in Europe they’re called “SmPCs”. The label’s content represents the formal, legal representation of what the drug can and cannot do, including side effects and potential hazards or toxicities. The label establishes the legal boundaries of what the medicine’s developers can promote (or “claim”) about its effects. Given the huge investment pharmaceutical companies make in each drug, the stronger their label claim , the better their chances their drug will be received by clinicians and patients. How does the FDA view the use of PRO’s in label claims? In 2009 the FDA released its Guidance for Industry, Patient Reported Outcomes: Use in Medical Product Development to Support Labeling Claims (PRO guidance) https://www.fda.gov/media/77832/download providing specific directives related to how PRO data can be used in a product’s label. A central tenet of the Guidance is that the PRO measure must demonstrate that it measures the construct on which the label claim is based. For example, if the pharma sponsor is hoping for a label claim that its drug improves patient quality of life (QoL) and functionality by reducing fatigue, it must use a PRO measure which has demonstrated it is a valid and reliable measure that is sensitive to changes in fatigue. The sponsor must concurrently demonstrate a correlation between fatigue and QoL Where do Clinical-Outcome-Assessment (COA’s) fit into label claims? COA’s and Patient Reported Outcome (PRO) Measures in particular, have become widely accepted as valid tools to incorporate in clinical trials to measure the patient’s perspective of his or her disease, treatment, condition or symptom. PROs are widely used in clinical trials to help sponsors differentiate their drug from others that may clinically perform similarly to other drugs. In many cases PRO’s can provide sensitive data for conditions that are not necessarily cured (like side effects), but instead might be mitigated to the point where the patient’s quality of life (QOL) or functional ability is enriched. These can be critical parameters to patients with chronic conditions; having a label claim which states that some aspect of life quality is improved while taking that drug can boost sales significantly. ​ From a statistical perspective, a PRO label claim can be based upon primary, secondary or (in some rare cases) exploratory study aims. Using PRO data as a primary endpoint requires that a direct link be established between the change in patient score and the disease, condition or symptom being treated. Using PRO data as a secondary study endpoint would mean that the PRO data would be used as either secondary to improvement in a clinical indication (i.e. the disease would be cured) OR to demonstrate there are other treatment benefits. An exploratory analysis is not typically used for labeling but may result in evidence or data that another study is warranted which focuses on a new finding. Per Gnanasakthy et al (2012 ) the majority of PRO label claims granted have been primary endpoints focused on symptoms. How does the EMA view the use of PRO’s in label claims? The EMA issued a reflection paper in 2005 which did not provide specific requirements, but rather was intended more as a reference document to provide some broad recommendations and context for the incorporation of Health- Related Quality of Life (HRQL) into the drug evaluation process. The FDA and EMA have differing standards for the use of PRO’s for labeling purposes. The FDA has strict recommendations requiring the validity of the construct being measured and also focuses more on clinical symptoms. The FDA also has more rigorous study design and analysis requirements. The EMA is more flexible with regard to open label studies and more amorphous patient-reported perspectives. Perhaps because of this, the EMA permitted more label claims in oncology trials from 2012-2016. During this period, according to Gnanasakthy et al ( 2019 ), 49 oncology drugs across 64 indications were approved by the EMA, however “no FDA labeling was identified.” It should be noted that the FDA’s Oncology Division has reviewed and approved PRO label claims for indications outside cancer, and other FDA divisions outside of oncology have approved PRO label claims. ​ We note that the EMA views FACIT measures favorably in oncology trials. Gnanasakthy et al (2019) note “A Functional Assessment of Cancer Therapy (FACT) measure was included in 12 (26.6%) submissions and led to labeling for 8 (38.1%) indications. Notably, FACT measures led to a proportionately greater share of EMA PRO labeling when included in a submission (8 of 12 [66.7%]) as compared to EORTC measures (9 of 26 [34.6%]). These 2 commonly used measures with their disease-specific modules were granted PRO labeling in two-thirds of reviews (14 of 21 [66.6%]).” What measures has FACITtrans translated that were used in label claims? FACITtrans has performed all the translations and linguistic validation for any FACIT measure so we are pleased to have contributed to any of our clients’ label claims that included a FACIT questionnaire in their QOL endpoint. ​ Confidentiality obligations do not permit us to specify which drugs used non-FACIT PRO’s translated by FACITtrans. Because we have been in this clinical trial “space” for nearly three decades, we are pleased to have contributed to many clients’ successful PRO label claims submissions. We can also state that as a preferred translation partner of the PROMIS instruments, we have collaborated in several studies’ multinational PROMIS claims submissions. The FACIT Group would like to specifically and gratefully acknowledge the contributions of Ari Gnanasakthy, M.Sc. at RTI Health Solutions and his colleagues who publish periodically on PRO’s in label claims.

BACK FACT-An Languages Afrikaans Albanian Arabic Bengali Bosnian Bulgarian Catalan Cebuano Chinese - Simplified Chinese - Traditional Croatian Czech Danish Dutch English Estonian Finnish French Georgian German Greek Gujarati Hebrew Hindi Hungarian Italian Indonesian Japanese Kannada Korean Latvian Lithuanian Macedonian Malay Malayalam Marathi Montenegrin Norwegian Odia Polish Portuguese Punjabi Romanian Russian Serbian Slovak Slovene Spanish Swedish Tagalog Tamil Telugu Thai Turkish Ukrainian Urdu Vietnamese Xhosa Zulu

BACK FACT-Ga Languages Afrikaans Arabic Chinese – Simplified Chinese – Traditional Croatian Czech Dutch English Estonian Finnish French Georgian German Greek Hebrew Hungarian Italian Japanese Korean Lithuanian Malay Norwegian Polish Portuguese Romanian Russian Serbian Spanish Swedish Tagalog Tamil Thai Turkish Ukrainian Vietnamese Zulu

BACK FACT-C Languages Arabic Bengali Bulgarian Chinese - Simplified Chinese – Traditional Croatian Czech Danish Dutch English Estonian Finnish French German Greek Gujarati Hebrew Hindi Hungarian Italian Japanese Kannada Korean Lithuanian Malay Malayalam Marathi Norwegian Polish Portuguese Punjabi Russian Serbian Slovak Spanish Swedish Telugu Thai Turkish Ukrainian

BACK FACIT-Pal-14 Scoring Downloads Download DOC

BACK FACT-HN Scoring Downloads Download DOC